Shang­hai star­tup's gene ther­a­py re­stores hear­ing in five deaf chil­dren, run­ning ahead of Lil­ly and Re­gen­eron tri­als

Five of six chil­dren who had been deaf since or soon af­ter birth can now hear af­ter re­ceiv­ing a gene ther­a­py de­vel­oped by Shang­hai Re­fresh­gene Ther­a­peu­tics, ac­cord­ing to a new study pub­lished in the Lancet Wednes­day.

The chil­dren in the tri­al had a mu­tat­ed ver­sion of a gene that en­codes otofer­lin, dis­rupt­ing sig­nal­ing to the brain from the ear’s sound-sens­ing hair cells. The ther­a­py, which is in­ject­ed in­to the in­ner ear, us­es a vi­ral vec­tor known as an AAV to de­liv­er a func­tion­al copy of the gene.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER